Research output: Contribution to journal › Article › peer-review
CNS genomic profiling in the mouse chronic social stress model implicates a novel category of candidate genes integrating affective pathogenesis. / Demin, Konstantin A.; Smagin, Dmitry A.; Kovalenko, Irina L.; Strekalova, Tatyana; Galstyan, David S.; Kolesnikova, Tatyana O.; De Abreu, Murilo S.; Galyamina, Anna G.; Bashirzade, Alim; Kalueff, Allan V.
In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 105, 110086, 01.03.2021, p. 110086.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - CNS genomic profiling in the mouse chronic social stress model implicates a novel category of candidate genes integrating affective pathogenesis
AU - Demin, Konstantin A.
AU - Smagin, Dmitry A.
AU - Kovalenko, Irina L.
AU - Strekalova, Tatyana
AU - Galstyan, David S.
AU - Kolesnikova, Tatyana O.
AU - De Abreu, Murilo S.
AU - Galyamina, Anna G.
AU - Bashirzade, Alim
AU - Kalueff, Allan V.
N1 - Publisher Copyright: © 2020 Elsevier Inc.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Despite high prevalence, medical impact and societal burden, anxiety, depression and other affective disorders remain poorly understood and treated. Clinical complexity and polygenic nature complicate their analyses, often revealing genetic overlap and cross-disorder heritability. However, the interplay or overlaps between disordered phenotypes can also be based on shared molecular pathways and ‘crosstalk’ mechanisms, which themselves may be genetically determined. We have earlier predicted (Kalueff et al., 2014) a new class of ‘interlinking’ brain genes that do not affect the disordered phenotypes per se, but can instead specifically determine their interrelatedness. To test this hypothesis experimentally, here we applied a well-established rodent chronic social defeat stress model, known to progress in C57BL/6J mice from the Anxiety-like stage on Day 10 to Depression-like stage on Day 20. The present study analyzed mouse whole-genome expression in the prefrontal cortex and hippocampus during the Day 10, the Transitional (Day 15) and Day 20 stages in this model. Our main question here was whether a putative the Transitional stage (Day 15) would reveal distinct characteristic genomic responses from Days 10 and 20 of the model, thus reflecting unique molecular events underlining the transformation or switch from anxiety to depression pathogenesis. Overall, while in the Day 10 (Anxiety) group both brain regions showed major genomic alterations in various neurotransmitter signaling pathways, the Day 15 (Transitional) group revealed uniquely downregulated astrocyte-related genes, and the Day 20 (Depression) group demonstrated multiple downregulated genes of cell adhesion, inflammation and ion transport pathways. Together, these results reveal a complex temporal dynamics of mouse affective phenotypes as they develop. Our genomic profiling findings provide first experimental support to the idea that novel brain genes (activated here only during the Transitional stage) may uniquely integrate anxiety and depression pathogenesis and, hence, determine the progression from one pathological state to another. This concept can potentially be extended to other brain conditions as well. This preclinical study also further implicates cilial and astrocytal mechanisms in the pathogenesis of affective disorders.
AB - Despite high prevalence, medical impact and societal burden, anxiety, depression and other affective disorders remain poorly understood and treated. Clinical complexity and polygenic nature complicate their analyses, often revealing genetic overlap and cross-disorder heritability. However, the interplay or overlaps between disordered phenotypes can also be based on shared molecular pathways and ‘crosstalk’ mechanisms, which themselves may be genetically determined. We have earlier predicted (Kalueff et al., 2014) a new class of ‘interlinking’ brain genes that do not affect the disordered phenotypes per se, but can instead specifically determine their interrelatedness. To test this hypothesis experimentally, here we applied a well-established rodent chronic social defeat stress model, known to progress in C57BL/6J mice from the Anxiety-like stage on Day 10 to Depression-like stage on Day 20. The present study analyzed mouse whole-genome expression in the prefrontal cortex and hippocampus during the Day 10, the Transitional (Day 15) and Day 20 stages in this model. Our main question here was whether a putative the Transitional stage (Day 15) would reveal distinct characteristic genomic responses from Days 10 and 20 of the model, thus reflecting unique molecular events underlining the transformation or switch from anxiety to depression pathogenesis. Overall, while in the Day 10 (Anxiety) group both brain regions showed major genomic alterations in various neurotransmitter signaling pathways, the Day 15 (Transitional) group revealed uniquely downregulated astrocyte-related genes, and the Day 20 (Depression) group demonstrated multiple downregulated genes of cell adhesion, inflammation and ion transport pathways. Together, these results reveal a complex temporal dynamics of mouse affective phenotypes as they develop. Our genomic profiling findings provide first experimental support to the idea that novel brain genes (activated here only during the Transitional stage) may uniquely integrate anxiety and depression pathogenesis and, hence, determine the progression from one pathological state to another. This concept can potentially be extended to other brain conditions as well. This preclinical study also further implicates cilial and astrocytal mechanisms in the pathogenesis of affective disorders.
KW - Anxiety
KW - depression
KW - Genomics
KW - Molecular mechanisms
KW - animal models
KW - Animal models
KW - Depression
KW - SEROTONIN TRANSPORTER
KW - OXIDATIVE STRESS
KW - MAJOR DEPRESSION
KW - ANXIETY-LIKE BEHAVIOR
KW - ESTROGEN-RECEPTOR
KW - POSITIVE FIGHTING EXPERIENCE
KW - AGONISTIC INTERACTIONS
KW - NEUROPSYCHIATRIC DISORDERS
KW - TRANSPORTER KNOCKOUT MICE
KW - INTERMEDIATE PHENOTYPES
UR - http://www.scopus.com/inward/record.url?scp=85094958084&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/8f1cddc1-7f93-3cdf-9938-c82c81212b9c/
U2 - 10.1016/j.pnpbp.2020.110086
DO - 10.1016/j.pnpbp.2020.110086
M3 - Article
C2 - 32889031
VL - 105
SP - 110086
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
M1 - 110086
ER -
ID: 62334275